Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of HZN-825 in idiopathic pulmonary fibrosis
NL-OMON53568Phase 2Active, not recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fipaxalparant in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Horizon Therapeutics. Primary endpoints: Change in forced vital capacity percent predicted and Change in forced vital capacity percent predicted at Week 104. Started Sep 2022; status: active, not recruiting.
02
Drugs
fipaxalparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON53568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53568.